Dödligt virus från Kina orsakar panik (SARS-CoV-2, COVID-19)

Abstract
Students at North American universities risk disenrollment due to third dose COVID-19 vaccine mandates. We present a risk-benefit assessment of boosters in this age group and provide five ethical arguments against mandates. We estimate that 22,000 - 30,000 previously uninfected adults aged 18-29 must be boosted with an mRNA vaccine to prevent one COVID-19 hospitalisation. Using CDC and sponsor-reported adverse event data, we find that booster mandates may cause a net expected harm: per COVID-19 hospitalisation prevented in previously uninfected young adults, we anticipate 18 to 98 serious adverse events, including 1.7 to 3.0 booster-associated myocarditis cases in males, and 1,373 to 3,234 cases of grade ≥3 reactogenicity which interferes with daily activities. Given the high prevalence of post-infection immunity, this risk-benefit profile is even less favourable. University booster mandates are unethical because: 1) no formal risk-benefit assessment exists for this age group; 2) vaccine mandates may result in a net expected harm to individual young people; 3) mandates are not proportionate: expected harms are not outweighed by public health benefits given the modest and transient effectiveness of vaccines against transmission; 4) US mandates violate the reciprocity principle because rare serious vaccine-related harms will not be reliably compensated due to gaps in current vaccine injury schemes; and 5) mandates create wider social harms. We consider counter-arguments such as a desire for socialisation and safety and show that such arguments lack scientific and/or ethical support. Finally, we discuss the relevance of our analysis for current 2-dose CCOVIDovid-19 vaccine mandates in North America.

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4206070

In this paper, we provide (to our knowledge) the first risk-benefit assessment of SARS-CoV-2 boosters for young previously uninfected adults under 40 years old. Our estimate suggests an expected net harm from boosters in this young adult age group, whereby the negative outcomes of all severe adverse events and hospitalizations may on average outweigh the expected benefits in terms of Covid-19 hospitalizations averted.

In this paper, we provide (to our knowledge) the first risk-benefit assessment of SARS-CoV-2 boosters for young previously uninfected adults under 40 years old. Our estimate suggests an expected net harm from boosters in this young adult age group, whereby the negative outcomes of all severe adverse events and hospitalizations may on average outweigh the expected benefits in terms of Covid-19 hospitalizations averted.

In this paper, we provide (to our knowledge) the first risk-benefit assessment of SARS-CoV-2 boosters for young previously uninfected adults under 40 years old. Our estimate suggests an expected net harm from boosters in this young adult age group, whereby the negative outcomes of all severe adverse events and hospitalizations may on average outweigh the expected benefits in terms of Covid-19 hospitalizations averted.